Volitionrx (VNRX) Current Deferred Revenue (2021 - 2025)

Volitionrx has reported Current Deferred Revenue for 5 years, with the latest figure at $353846.0 in Q4 2025.

• For the quarter ending Q4 2025, Current Deferred Revenue rose 53.85% year-over-year to $353846.0; the trailing twelve-month figure through Dec 2025 stood at $353846.0 (up 53.85% YoY), and the FY2025 full-year result was $353846.0, up 53.85% from the prior year.
• Current Deferred Revenue for Q4 2025 stood at $353846.0, roughly flat from $354000.0 in the prior quarter.
• The five-year high for Current Deferred Revenue was $12.5 billion in Q4 2021, with the low at $101097.0 in Q2 2024.
• Historically, Current Deferred Revenue has averaged $788.1 million across 5 years, with a median of $5.2 million in 2022.
• The largest YoY upside for Current Deferred Revenue was 19447.79% in 2024 against a maximum downside of 99.0% in 2024.
• Volitionrx's Current Deferred Revenue stood at $12.5 billion in 2021, then tumbled by 99.92% to $10.0 million in 2022, then jumped by 130.0% to $23.0 million in 2023, then sank by 99.0% to $230000.0 in 2024, then soared by 53.85% to $353846.0 in 2025.
• The last three Current Deferred Revenue figures came in at $353846.0 (Q4 2025), $354000.0 (Q3 2025), and $122441.0 (Q2 2025), per Business Quant data.